A Phase 2 Study of GTI-2040 (NSC 722929) in Combination With Capecitabine in Metastatic Breast Cancer

Trial Profile

A Phase 2 Study of GTI-2040 (NSC 722929) in Combination With Capecitabine in Metastatic Breast Cancer

Completed
Phase of Trial: Phase II

Latest Information Update: 22 Oct 2016

At a glance

  • Drugs LOR 2040 (Primary) ; Capecitabine
  • Indications Advanced breast cancer; Male breast cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 18 Jan 2013 Additional lead trial centre deleted as reported by ClinicalTrials.gov record.
    • 14 Jun 2011 Actual end date (Mar 2010) added as reported by ClinicalTrials.gov.
    • 14 Jun 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top